{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T05:56:00Z","timestamp":1747202160855,"version":"3.40.5"},"reference-count":0,"publisher":"RCVS Knowledge","issue":"4","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VE"],"abstract":"<jats:p>PICO Question\nAre felinised anti-nerve growth factor monoclonal antibodies (frunevetmab) effective at reducing the clinical signs of pain and immobility in cats with degenerative joint disease when compared with no treatment?\n\u00a0\nClinical bottom line\nCategory of research\nTreatment.\n\u00a0\nNumber and type of study designs reviewed\nThree peer-reviewed randomised controlled trial treatment studies, two of which were pilot studies.\n\u00a0\nStrength of evidence \nModerate.\n\u00a0\nOutcomes reported\nAll three studies concluded that there was a statistical reduction in pain and an improvement in mobility in the groups administered frunevetmab, when compared to the groups administered the placebo.\n\u00a0\nConclusion\nThere is moderate evidence suggesting that the administration of frunevetmab by injection led to a reduction in pain and an increase in mobility. Injections were given at day 0; day 0 and 28, or day 0, 28 and 56 depending on the study. Further research should be conducted to ensure repeatability, involving more objectively measured outcomes to reduce the reliance on subjective measures which are more likely to have associated bias.\n\u00a0\nHow to apply this evidence in practice\nThe application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient\u2019s circumstances and owners\u2019 values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.\nKnowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.<\/jats:p>","DOI":"10.18849\/ve.v8i4.623","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:53:29Z","timestamp":1697619209000},"source":"Crossref","is-referenced-by-count":0,"title":["The effect of anti-nerve growth factor monoclonal antibodies on the clinical signs of degenerative joint disease in cats"],"prefix":"10.18849","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1437-2919","authenticated-orcid":false,"given":"Lydia","family":"Seeley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"8083","published-online":{"date-parts":[[2023,10,18]]},"container-title":["Veterinary Evidence"],"original-title":[],"link":[{"URL":"https:\/\/veterinaryevidence.org\/index.php\/ve\/article\/download\/623\/918","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/veterinaryevidence.org\/index.php\/ve\/article\/download\/623\/918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:53:31Z","timestamp":1697619211000},"score":1,"resource":{"primary":{"URL":"https:\/\/veterinaryevidence.org\/index.php\/ve\/article\/view\/623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.18849\/ve.v8i4.623","relation":{},"ISSN":["2396-9776"],"issn-type":[{"type":"electronic","value":"2396-9776"}],"subject":[],"published":{"date-parts":[[2023,10,18]]}}}